GOSS Investors Invited to Lead Securities Fraud Lawsuit Against Gossamer Bio

The Schall Law Firm reminds investors of a class action lawsuit against Gossamer Bio, Inc. for violations of securities laws.

Apr. 3, 2026 at 4:09am

Got story updates? Submit your updates here. ›

A photorealistic studio still life featuring a metal gavel, legal documents, and reading glasses arranged on a clean, monochromatic background, symbolizing the abstract concepts of corporate governance, financial risk, and legal proceedings.A legal case alleging securities fraud by a biotech firm underscores the importance of transparency and accuracy in public company disclosures.Los Angeles Today

The Schall Law Firm, a national shareholder rights litigation firm, is reminding investors of a class action lawsuit against Gossamer Bio, Inc. (NASDAQ: GOSS) for violations of securities laws. Investors who purchased the company's securities between June 16, 2025 and February 20, 2026 are encouraged to contact the firm before June 1, 2026 to participate in the lawsuit.

Why it matters

This lawsuit alleges that Gossamer Bio made false and misleading statements to the market about the design of its Phase 3 PROSERA study, which concealed adverse facts and resulted in damages to investors when the truth was revealed.

The details

The lawsuit claims Gossamer Bio violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 by making false and misleading statements about the PROSERA study, particularly regarding controls for placebo response at certain testing sites. These alleged misrepresentations are said to have artificially inflated the company's stock price during the class period.

  • The class period is from June 16, 2025 to February 20, 2026.
  • The deadline to contact the Schall Law Firm to participate in the lawsuit is June 1, 2026.

The players

The Schall Law Firm

A national shareholder rights litigation firm that is representing investors in this class action lawsuit against Gossamer Bio.

Gossamer Bio, Inc.

A biopharmaceutical company that is the defendant in this securities fraud lawsuit.

Got photos? Submit your photos here. ›

What they’re saying

“We encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge.”

— Brian Schall, Attorney, Schall Law Firm

What’s next

The class in this case has not yet been certified, and until certification occurs, investors are not represented by an attorney. Those who wish to participate in the lawsuit must contact the Schall Law Firm before the June 1, 2026 deadline.

The takeaway

This lawsuit highlights the importance of transparency and accuracy in public company disclosures, as investors rely on this information to make informed decisions. The outcome of this case could have broader implications for the biotechnology industry and shareholder rights.